What is the price target for USNA stock?
6 analysts have analysed USNA and the average price target is 39.78 USD. This implies a price increase of 103.79% is expected in the next year compared to the current price of 19.52.
NYSE:USNA • US90328M1071
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for USANA HEALTH SCIENCES INC (USNA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-02-27 | DA Davidson | Maintains | Neutral -> Neutral |
| 2025-01-02 | DA Davidson | Maintains | Neutral -> Neutral |
| 2024-10-23 | DA Davidson | Maintains | Neutral -> Neutral |
| 2024-07-25 | DA Davidson | Maintains | Neutral -> Neutral |
| 2024-05-07 | DA Davidson | Maintains | Neutral -> Neutral |
| 2024-02-22 | DA Davidson | Maintains | Neutral -> Neutral |
| 2023-10-25 | DA Davidson | Maintains | Neutral -> Neutral |
| 2023-04-26 | DA Davidson | Maintains | Neutral |
| 2023-02-13 | DA Davidson | Maintains | Neutral |
| 2022-10-27 | DA Davidson | Maintains | Neutral |
| 2022-07-28 | DA Davidson | Maintains | Neutral |
| 2022-07-12 | DA Davidson | Maintains | Neutral |
| 2022-07-07 | Jefferies | Downgrade | Hold -> Underperform |
| 2022-04-27 | DA Davidson | Maintains | Neutral |
| 2022-04-14 | DA Davidson | Initiate | Neutral |
| 2021-02-10 | Roth Capital | Maintains | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 921.01M -7.77% | 854.503M -7.22% | 925.257M 8.28% | 961.3M 3.90% | 1.021B 6.21% | |
| EBITDA YoY % growth | 105.773M -12.58% | 80.863M -23.55% | 83.424M 3.17% | 104.39M 25.13% | 127.31M 21.96% | |
| EBIT YoY % growth | 93.071M -13.50% | 66.324M -28.74% | 50.862M -23.31% | 52.035M 2.31% | 75.099M 44.32% | |
| Operating Margin | 10.11% | 7.76% | 5.50% | 5.41% | 7.36% | |
| EPS YoY % growth | 3.30 -8.08% | 2.60 -21.21% | 1.92 -26.15% | 2.04 6.25% | 2.83 38.50% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.45 -38.52% | 0.46 -37.97% | 0.46 406.00% | 0.67 12.20% | 0.65 45.45% | 0.66 44.44% | 0.75 64.44% | 0.77 13.64% |
| Revenue Q2Q % growth | 246.18M -1.35% | 242.7M 2.84% | 231.3M 8.08% | 241.12M 6.60% | 258.87M 5.15% | 257.76M 6.21% | 246.2M 6.44% | 258.36M 7.15% |
| EBITDA Q2Q % growth | 22.687M -5.51% | 25.617M -21.90% | 22.887M -9.27% | 33.197M -33.35% | 29.353M 29.38% | 31.611M 23.40% | 32.61M 42.48% | 33.738M 1.63% |
| EBIT Q2Q % growth | 9.638M -38.50% | 12.564M -24.85% | 9.813M 701.72% | 20.021M 16.07% | 16.328M 69.41% | 18.592M 47.98% | 19.535M 99.07% | 20.644M 3.11% |
All data in USD
6 analysts have analysed USNA and the average price target is 39.78 USD. This implies a price increase of 103.79% is expected in the next year compared to the current price of 19.52.
USANA HEALTH SCIENCES INC (USNA) will report earnings on 2026-05-05, after the market close.
The consensus EPS estimate for the next earnings of USANA HEALTH SCIENCES INC (USNA) is 0.45 USD and the consensus revenue estimate is 246.18M USD.